BLFS officer sale: 419 shares at $27.36; holdings now 193,253
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
BioLife Solutions (BLFS) reported an insider transaction by its Chief Quality and Operations officer. On 10/09/2025, the reporting person sold 419 shares of common stock at $27.36 per share in a transaction coded “S.” The filing states this sale was made under a Rule 10b5-1(c) trading plan adopted effective 01-03-2023 to satisfy tax withholding obligations upon the vesting of restricted stock.
Following the sale, the reporting person beneficially owned 193,253 shares, held directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 419 shares ($11,464)
Net Sell
1 txn
Insider
Foster Karen A.
Role
Chief Quality and Operations
Sold
419 shs ($11K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 419 | $27.36 | $11K |
Holdings After Transaction:
Common Stock — 193,253 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What did BLFS report in this Form 4?
A company officer reported selling 419 shares of common stock at $27.36 on 10/09/2025.
Was the BLFS sale under a 10b5-1 plan?
Yes. The sale was made under a Rule 10b5-1(c) plan adopted effective 01-03-2023.
Who is the BLFS reporting person’s role?
The reporting person is an Officer, titled Chief Quality and Operations.
What was the transaction code for the BLFS sale?
It was coded S (sale).